Pathstone Holdings
TVRD

Pathstone Holdings’s Tvardi Therapeutics TVRD Stock Holding History

Pathstone Holdings’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-343
Closed -$9.16K – 2362
2023
Q4 		$9.16K Buy
+343
New +$14.2K ﹤0.01% 2194

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Pathstone Holdings's TVRD Position: Q1 2024 in Review

Pathstone Holdings sold out of Tvardi Therapeutics (TVRD) in Q1 2024, closing a stake of 343 shares — an estimated $9.16K sold.

Pathstone Holdings first reported a position in TVRD in Q4 2023 and held it in 1 quarter. The position peaked at $9.16K in Q4 2023. 97 funds tracked by Wall St. Rank hold TVRD as of Q1 2024.

  • Pathstone Holdings reported no remaining Tvardi Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Pathstone Holdings sold 343 Tvardi Therapeutics shares in Q1 2024, an estimated $9.16K.
  • Pathstone Holdings first reported a position in Tvardi Therapeutics in Q4 2023 and held it in 1 quarter.
  • Pathstone Holdings's Tvardi Therapeutics position peaked at $9.16K in Q4 2023.
  • 97 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2024.

Based on Pathstone Holdings's 13F filing for Q1 2024, filed 13 May 2024.